Knight Therapeutics, Inc. · TSX:GUD
Knight Therapeutics — Investor Presentation (August 2019)
29 slides from Knight Therapeutics's investor presentation, August 2019
Slide 1: Building Canada's leading specialty pharmaceutical company
Building Canada’s leading specialty pharmaceutical company Knight Therapeutics Inc. (TSX: GUD) 1 August 2019
Slide 2: Forward Looking Statements
Forward Looking Statements This document contains forward-looking statements for the Company and its subsidiaries. These forward looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forwar
Slide 3: A Knight is Born
A Knight is Born • Better a GUD Knight than a bad one • We never rest at Knight • May you always have a GUD-Knight • Knighting wrong with making money • GUD for Knight • Fun things happen at Knight • Knight loves a GUD pun • GUD Knight sleep tight • GUD time had by all • GUD luck Jonathan 3
Slide 4: A Knight's History
A Knight’s History • Founded by co-founder & CEO of Paladin Labs Inc. – 19 years of consecutive record revenues – Share price increased from $1.50 to $151 per share – Market capitalization increased from $6 million to $3.2 billion • Knight’s first day was on February 28th, 2014 – The day Paladin’s s
Slide 5: Why Invest in Knight?
Why Invest in Knight? Disciplined capital stewardship and relentless focus on our long-term strategy Knight’s Consistent Investment Attributes Successes at Knight to Date Proven leadership with alignment, expertise Raised $685M at increasing valuations and determination to build Paladin 2.0 In
Slide 6: Growth Strategies
Growth Strategies Firing on Multiple Cylinders • In-license or acquire innovative pharmaceuticals in Canada and select “rest of world” markets • Acquire mature or “under-promoted” products from Big Pharma In-licensing or Acquiring • Develop near-term, low risk / low expense products Product Rights •
Slide 7: Product Portfolio
Product Portfolio Expanding Pipeline of Innovative Pharmaceuticals 7
Slide 8: Product Selection Criteria
Product Selection Criteria Taking on Commercialization Risk, NOT Development Risk • Knight takes on late-stage commercialization risk, not early-stage development risk with lower probability of success • Focus on later stage products (Phase II, Phase III or approved in foreign markets) with lower cl
Slide 9: Pain Support
Pain Support Two innovative products for opioid supportive care Movantik® for the treatment of opioid-induced constipation Probuphine™ a novel implant for opioid dependence • Exclusive license agreement with AstraZeneca for • Exclusive in-license agreement with Titan for Canada Movantik® in Canada a
Slide 10: Ibsrela (Tenapanor)
Ibsrela™ (Tenapanor) Unique mechanism of action to treat IBS-C Background • Exclusive in-license agreement with Ardelyx for Canada • First-in-class, proprietary, minimally absorbed, oral product • New Drug Application submitted to FDA in September 2018 for IBS-C • Completed one Phase IIb/III study i
Slide 11: Ophthalmology Portfolio
Ophthalmology Portfolio Differentiated therapies for targeted physicians Iluvien® Netildex™ (Implant for diabetic macular edema) (Combination antibiotic/steroid for eye infection/inflammation) • Exclusive in-license agreement with Alimera Sciences • Exclusive in-license agreement with SIFI for Netil
Slide 12: Women's Health Portfolio
Women’s Health Portfolio Two complementary unique late-stage women’s health products • Exclusive in-license agreement with TherapeuticsMD for Canada and Israel • Leverage of Knight’s balance sheet through $20M USD equity investment in TherapeuticsMD • Knight expects to submit both products for appro
Slide 13: Nerlynx
Nerlynx™ Novel treatment for HER2 positive breast cancer Background • Exclusive in-license agreement with Puma Biotechnology for Canada • Received regulatory approval from Health Canada in July 2019 • Indicated for extended adjuvant treatment of early stage HER2+ breast cancer • Irreversible pan-HER
Slide 14: Growing and Diverse Pipeline
Growing and Diverse Pipeline An impressive portfolio of innovative prescription pharmaceuticals, prioritizing 4 therapeutic areas Therapeutic Area Product Licensor Indication / Potential Indication Status Transaction Date NCE IP Marketed in CAN & Movantik® AstraZeneca Opioid-induced constipation Dec
Slide 15: Growing and Diverse Pipeline
Growing and Diverse Pipeline An impressive portfolio of innovative prescription pharmaceuticals, prioritizing 4 therapeutic areas Therapeutic Area Product Licensor Indication / Potential Indication Status Transaction Date NCE IP AzaSite™ Akorn Bacterial conjunctivitis Approved July 2015 - Ophthalm
Slide 16: Rest of World Pharma
Rest of World Pharma Finding Other Knights 16
Slide 17: Rest of World Strategy
Rest of World Strategy Identify markets with attractive growth profiles ROW (ex-US, Target Geographies Europe, Japan, China) specialty pharma will continue to grow • High-growth countries with expanding access and funding for medicines Leveraging [13+] • Stable legal and regulatory systems, Partner
Slide 18: Strategic Lending
Strategic Lending Another Source of Products and Return on Investment 18
Slide 19: Strategic Lending Overview
Strategic Lending Overview Leveraging the balance sheet to source additional products and an attractive return Nominal • Secured loans with life-sciences companies Company Loan Balance(1) Interest Rate Maturity Product Rights in exchange for product rights or pipeline assets for Canada and select in
Slide 20: Strategic Lending Supports Growth
Strategic Lending Supports Growth Secured loans with Moksha8 (US$10M) and Triumvira (US$5M) Securing ROW infrastructure Securing product rights • Loaned US$10M to date at 15% interest rate, maturing • Access to early stage, novel T cell technology with early 2024, fully secured. Remaining commitment
Slide 21: Strategic Fund Investment
Strategic Fund Investment Long-term Path for Product Rights 21
Slide 22: Strategic Fund Investment Overview
Strategic Fund Investment Overview Attractive financial return with product access upside optionality Fund Amount Stage Geography • Fund investments were made to obtain preferential access to innovative products Teralys $30.0M VCAP Fund of funds Canada for Canadian market Domain US$25.0M Early stage
Slide 23: Why Knight?
Why Knight? Partner of Choice for Canada and RoW 23
Slide 24: Knight's Management Experience
Knight’s Management Experience Building Bench Strength • Built Canadian business through collaborations with over 30 companies Partnering • Deals structured to meet partners’ needs • Significant experience in all aspects of the regulatory process Regulatory • ~30 submissions to Health Canada with a
Slide 25: Management Team
Management Team Jonathan Ross Goodman B.A., LL.B., M.B.A. Chief Executive Officer • Paladin Labs, Co-Founder, President & CEO • Procter & Gamble, Brand Management Samira Sakhia, CPA, M.B.A. President and Chief Financial Officer • Paladin Labs, Chief Financial Officer Amal Khouri, B.Sc., M.B.A. VP Bu
Slide 26: Board of Directors
Board of Directors Knight has a highly skilled and experienced Board of Directors Board Member Qualifications James Gale • Paladin Labs, Board member from 2008 to 2014 (Chairman) • Signet Healthcare Partners, Managing Director Jonathan Ross • Knight Therapeutics, Founder and CEO Goodman • Paladin La
Slide 27: Financial and Strategic Assets
Financial and Strategic Assets Asset Description Cash and marketable securities $745 million1 ($5.22 / share) Key Marketed Products Movantik®, Impavido®, Probuphine™, Burinex® Approved Products Iluvien®, Nerlynx® Products Pending Approval Netildex™, Ibsrela® Products Pending Submission Bijuva™ (TX-0
Slide 28: Summary
Summary • Experienced and dynamic management team • Proven ability to develop a rich pipeline of new products • Proven ability to secure mutually beneficial transactions • Proven track record of profitable growth • Financial strength to execute our strategy 28
Slide 29: Knight Therapeutics Inc. (TSX: GUD)
Building Canada’s leading specialty pharmaceutical company Knight Therapeutics Inc. (TSX: GUD) 29 August 2019
Knight Therapeutics — Investor Presentation (August 2019) on 6ix